Bristol-Myers Squibb

In April 2021, Bristol-Myers Squibb and PsiOxus announced an updated agreement to advance its clinical collaboration. The first stage of this collaboration combined Bristol Myers Squibb’s Opdivo with PsiOxus’ enadenotucirev in the Phase 1 SPICE study to determine the safety and tolerability of combining these two agents, and to optimise the combination intravenous dosing regimen. The revised collaboration announced today will build upon the initial study data and will combine Opdivo with PsiOxus’ NG-641.
View the collaboration announcement here.


Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu